Recent Applications of Retro-Inverso Peptides
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Natural and de novo designed peptides are gaining an ever-growing interest as drugs against several diseases. Their use is however limited by the intrinsic low bioavailability and poor stability. To overcome these issues retro-inverso analogues have been investigated for decades as more stable surrogates of peptides composed of natural amino acids. Retro-inverso peptides possess reversed sequences and chirality compared to the parent molecules maintaining at the same time an identical array of side chains and in some cases similar structure. The inverted chirality renders them less prone to degradation by endogenous proteases conferring enhanced half-lives and an increased potential as new drugs. However, given their general incapability to adopt the 3D structure of the parent peptides their application should be careful evaluated and investigated case by case. Here, we review the application of retro-inverso peptides in anticancer therapies, in immunology, in neurodegenerative diseases, and as antimicrobials, analyzing pros and cons of this interesting subclass of molecules.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bloom (2014) · doi:10.1001/jamaneurol.2013.5847 · Cited by 2,194
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960 · cited 1×
“Also, no significant improvements in terms of reduction of symptoms and immunological adverse reactions in patients [108] were observed with bapineuzumab, a humanized anti-Aβ1–42 monoclonal antibody (mAb).”
BackgroundBarczyk, M., Carracedo, S., & Gullberg, D. (2010) · Cell and Tissue Research · doi:10.1007/s00441-009-0834-6 · Cited by 1,512
Antimicrobial host defence peptides: functions and clinical potential
Mookherjee, N., Anderson, M. A., Haagsman, H. P., & Davidson, D. J. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0058-8 · Cited by 1,502
The final steps of integrin activation: the end game
Shattil, S. J., Kim, C., & Ginsberg, M. H. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2871 · Cited by 1,086 · cited 1×
“Integrins [80,81] are other receptors playing important roles in cell–cell and cell–matrix interactions during developmental and pathological processes [80,82,83].”
BackgroundIntegrins and cancer: regulators of cancer stemness, metastasis, and drug resistance
Seguin, L., Desgrosellier, J. S., Weis, S. M., & Cheresh, D. A. (2015) · Trends in Cell Biology · doi:10.1016/j.tcb.2014.12.006 · Cited by 685
Strategic Approaches to Optimizing Peptide ADME Properties
Di, L. (2015) · The AAPS Journal · doi:10.1208/s12248-014-9687-3 · Cited by 669
Inflammatory components in human Alzheimer’s disease and after active amyloid-β42 immunization
Zotova, E., Bharambe, V., Cheaveau, M., Morgan, W., Holmes, C., Harris, S., Neal, J. W., Love, S., Nicoll, J. A. R., & Boche, D. (2013) · Brain · doi:10.1093/brain/awt210 · Cited by 272 · cited 1×
“In the case of Alzheimer’s disease (AD), advanced approaches were initially based on direct immunization with Aβ1–42, although the first clinical trials were stopped due to adverse effects involving detrimental T-cell mediated brain inflammation [107].”
BackgroundLopez-Medina, E., Fan, D., Coughlin, L. A., Ho, E. X., Lamont, I. L., Reimmann, C., Hooper, L. V., & Koh, A. Y. (2015) · PLOS Pathogens · doi:10.1371/journal.ppat.1005129 · Cited by 143
Fischer, P. (2003) · Current Protein & Peptide Science · doi:10.2174/1389203033487054 · Cited by 123
Cited by
Unlocking the Potential of Retro-Inverso (RI) Peptides as Future Drug Candidates
Al Musaimi, O. (2024) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-024-10639-1 · Cited by 18
“For further readings about the applications of RI in cancer, immunology, neurodegenerative, and antimicrobials, readers are encouraged to refer to the detailed review by Doti et al. (Doti et al. 2021).”
Different directions for retro‐inverso peptides
Preston, G. W. (2022) · Journal of Peptide Science · doi:10.1002/psc.3384 · Cited by 10
“For further examples, readers are directed to the recent review by Doti et al.3 Before delving into the applications, let us consider the relationship between the RI and original versions of a peptide in a little more detail.”
Method
Metadata
- Authors
- Doti, N., Mardirossian, M., Sandomenico, A., Ruvo, M., & Caporale, A.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-08-12
- Volume
- 22
- Issue
- 16
- Pages
- 8677
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W3189436433
- Cited by
- 89
- References
- 13
- FWCI
- 3.69
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recent Applications of Retro-Inverso Peptides. https://app.cochat.ai/papers/10.3390/ijms22168677
- The paper
- Doti, N., Mardirossian, M., Sandomenico, A., Ruvo, M., & Caporale, A. (2021). Recent Applications of Retro-Inverso Peptides. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms22168677
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.